Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida.
J Reconstr Microsurg. 2023 May;39(4):245-253. doi: 10.1055/s-0041-1732432. Epub 2022 Jan 10.
Collagen and human amniotic membrane (hAM) are Food and Drug Administration (FDA)-approved biomaterials that can be used as nerve wraps or conduits for repair of peripheral nerve injuries. Both biomaterials have been shown to reduce scarring and fibrosis of injured peripheral nerves. However, comparative advantages and disadvantages have not been definitively shown in the literature. The purpose of this systematic review is to comprehensively evaluate the literature regarding the roles of hAM and collagen nerve wraps and conduits on peripheral nerve regeneration in preclinical models.
The MEDLINE database was queried using the PubMed search engine on July 7, 2019, with the following search strategy: ("amniotic membrane" OR "amnion") OR ("collagen conduit" OR "nerve wrap")] AND "nerve." All resulting articles were screened by two independent reviewers. Nerve type, lesion type/injury model, repair type, treatment, and outcomes were assessed.
Two hundred and fifty-eight articles were identified, and 44 studies remained after application of inclusion and exclusion criteria. Seventeen studies utilized hAM, whereas 27 studies utilized collagen wraps or conduits. Twenty-three (85%) of the collagen studies utilized conduits, and four (15%) utilized wraps. Six (35%) of the hAM studies utilized conduits and 11 (65%) utilized wraps. Two (9%) collagen studies involving a conduit and one (25%) involving a wrap demonstrated at least one significant improvement in outcomes compared with a control. While none of the hAM conduit studies showed significant improvements, eight (73%) of the studies investigating hAM wraps showed at least one significant improvement in outcomes.
The majority of studies reported positive outcomes, indicating that collagen and hAM nerve wraps and conduits both have the potential to enhance peripheral nerve regeneration. However, relatively few studies reported significant findings, except for studies evaluating hAM wraps. Preclinical models may help guide clinical practice regarding applications of these biomaterials in peripheral nerve repair.
胶原蛋白和人羊膜(hAM)是获得美国食品和药物管理局(FDA)批准的生物材料,可作为神经包裹物或导管用于修复周围神经损伤。这两种生物材料都已被证明可以减少受伤周围神经的瘢痕形成和纤维化。然而,在文献中尚未明确显示它们的相对优势和劣势。本系统评价的目的是全面评估文献中关于 hAM 和胶原蛋白神经包裹物和导管在外周神经再生中的作用的研究。
2019 年 7 月 7 日,通过 PubMed 搜索引擎在 MEDLINE 数据库中进行了检索,使用的搜索策略为:(“羊膜”或“amnion”)或(“胶原蛋白导管”或“神经包裹物”)]和“神经”。由两位独立的审查员筛选所有结果文章。评估神经类型、病变类型/损伤模型、修复类型、治疗和结果。
共确定了 258 篇文章,应用纳入和排除标准后,有 44 项研究保留。17 项研究使用了 hAM,而 27 项研究使用了胶原蛋白包裹物或导管。27 项胶原蛋白研究中有 23 项(85%)使用了导管,4 项(15%)使用了包裹物。17 项 hAM 研究中有 6 项(35%)使用了导管,11 项(65%)使用了包裹物。涉及导管的 2 项(9%)胶原研究和涉及包裹物的 1 项(25%)胶原研究在结果方面至少有一项显著改善。虽然没有一项 hAM 导管研究显示出显著改善,但 8 项(73%)研究 hAM 包裹物的研究在结果方面至少有一项显著改善。
大多数研究报告了积极的结果,表明胶原蛋白和 hAM 神经包裹物和导管都有可能增强周围神经再生。然而,除了评估 hAM 包裹物的研究外,相对较少的研究报告了显著的发现。临床前模型可能有助于指导这些生物材料在周围神经修复中的应用的临床实践。